1 year return (CAGR)
3.38%
Kamada Exchange (TA, ILA)
KMDA.TA
23.66
-0.06 (-0.25%)
HealthcareDrug Manufacturers - Specialty & Generic
Loading...
3 year return (CAGR)
3.53%
5 year return (CAGR)
6.09%
10 year return (CAGR)
5.00%
Adobe 2026 Q3 – Is sentiment driving the price?
Read MoreMarketcap
1.40B
Price/Sales
7.27
Ent value
1.48B
Price/Book
-
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
55.54%
Trailing P/E
62.88
PEG
-
Forward P/E
-
EPS growth
-
Stock information
What is a stock exchange? Operation, actors, examples
Read MoreStock chart
Loading...
Stock price data
| Open | 24.25 |
| Daily high | 25.46 |
| Daily low | 24.06 |
| Daily Volume | 85K |
| All-time high | 6200.00 |
| 1y analyst estimate | 11.00 |
| Beta | 0.13 |
| EPS (TTM) | 0.38 |
| Dividend per share | 0.00 |
| Ex-div date | 27 Aug 2026 |
| Next earnings date | 4 Mar 2026 |
Downside potential
Loading...
Downside potential data
| KMDA.TA | S&P500 | |
| Current price drop from All-time high | -99.62% | -0.66% |
| Highest price drop | -99.67% | -56.47% |
| Date of highest drop | 12 Aug 2026 | 9 Mar 2009 |
| Avg drop from high | -54.30% | -10.67% |
| Avg time to new high | 86 days | 12 days |
| Max time to new high | 3083 days | 1805 days |
News
Company Expects Growing Biosimilar Product Portfolio, Commercialized in Israel and the MENA Region, to Generate Approximately $10 Million in Annual Revenue in 2028 and Approximately $20 Million-$25 Mi...
October 6, 2026
Kamada (NASDAQ:KMDA) outlined its growth strategy, product portfolio and financial outlook during a company presentation, emphasizing demand for specialty plasma-derived therapies and a plan to expand...
September 27, 2026
U.S. Centers for Disease Control and Prevention (CDC) Reports a Significant Year-Over-Year Increase in Nationwide Rabies Exposures and Rabies Immunoglobulin Utilization KedRAB is One of Only Two FDA-A...
September 17, 2026
REHOVOT, Israel, and HOBOKEN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for...
September 10, 2026
REHOVOT, Israel and HOBOKEN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed product...
September 3, 2026
KEDRAB sales and distribution expansion drive record revenue and EBITDA growth.
August 19, 2026
Dividend to be Paid Consistent with the Company's Cash Dividend PolicyREHOVOT, Israel and HOBOKEN, N.J., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharma...
August 17, 2026
Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.
August 14, 2026
The consensus price target hints at a 79.1% upside potential for Kamada (KMDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r...
August 14, 2026